{
  "id": "mhgap#referral_3c2f4450",
  "content": "requiring long-term treatment, carefully balancing effectiveness, side-effects and\nindividual preference.\nConditional recommendation. Moderate certainty of evidence.\nxxviii\nExecutive summary\nTABLE 1. (continued) Summary of recommendations\nModule and Recommendation\nrecommendation\nStrength of the recommendation and certainty of the evidence\nnumber\nPSY5 (update) 5.1 Oral antipsychotic medicines – namely aripiprazole, olanzapine, paliperidone,\nquetiapine, risperidone – should be considered under specialist supervision for\nadolescents with psychotic disorders (including schizophrenia), carefully balancing\neffectiveness, side-effects and individual preference.\nConditional recommendation. Low certainty of evidence.\n5.2 Clozapine should be considered for adolescents with a treatment-resistant psychotic\ndisorder (including schizophrenia) under specialist supervision, carefully balancing\neffectiveness, side-effects and individual preference.\nConditional recommendation. Low certainty of evidence.\nPSY6 (update) Psychotropic medicines (antipsychotic medicines, namely aripiprazole, olanzapine,\nquetiapine, risperidone; and mood stabilizers, namely lithium) should be considered\nunder specialist supervision for adolescents with bipolar disorder (current episode manic),\ncarefully balancing effectiveness, side-effects and individual preference.\nConditional recommendation. Very low certainty of evidence.\nPSY7 (update) 7.1 Oral antipsychotic medicines (namely aripiprazole, haloperidol, olanzapine,\npaliperidone or quetiapine) or mood stabilizers (namely carbamazepine, lithium, valproic\nacid [sodium valproate]) should be offered to adults with bipolar disorder (current episode\nmania), carefully balancing effectiveness, side-effects and individual preference.\nStrong recommendation. Low certainty of evidence.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Referral requiring long-term treatment, carefully balancing effectiveness, side-effects and\nindividual preference.\nConditional recommendation. Moderate certainty of evidence.\nxxviii\nExecutive summary\nTABLE 1. (continued) Summary of recommendations\nModule and Recommendation\nrecommendation\nStrength of the recommendation and certainty of the evidence\nnumber\nPSY5 (update) 5.1 Oral antipsychotic medicines – namely aripiprazole, olanzapine, paliperidone,\nquetiapine, risperidone – should be considered under specialist supervision for\nadolescents with psychotic disorders (including schizophrenia), carefully balancing\neffectiveness, side-effects and individual preference.\nConditional recommendation. Low certainty of evidence.\n5.2 Clozapine should be considered for adolescents with a treatment-resistant psychotic\ndisorder (including schizophrenia) under specialist supervision, carefully balancing\neffectiveness, side-effects and individual preference.\nConditional recommendation. Low certainty of evidence.\nPSY6 (update) Psychotropic medicines (antipsychotic medicines, namely aripiprazole, olanzapine,\nquetiapine, risperidone; and mood stabilizers, namely lithium) should be considered\nunder specialist supervision for adolescents with bipolar disorder (current episode manic),\ncarefully balancing effectiveness, side-effects and individual preference.\nConditional recommendation. Very low certainty of evidence.\nPSY7 (update) 7.1 Oral antipsychotic medicines (namely aripiprazole, haloperidol, olanzapine,\npaliperidone or quetiapine) or mood stabilizers (namely carbamazepine, lithium, valproic\nacid [sodium valproate]) should be offered to adults with bipolar disorder (current episode\nmania), carefully balancing effectiveness, side-effects and individual preference.\nStrong recommendation. Low certainty of evidence. Requiring long-term treatment, carefully balancing effectiveness, side-effects and\nindividual preference. conditional recommendation."
}